A comparison of palonosetron and dexamethasone for postoperative nausea and vomiting in orthopedic patients receiving patient-controlled epidural analgesia

Byung-Gun Kim, Hyunzu Kim, Hyun-Kyoung Lim, Chunwoo Yang, Sora Oh, and Byung-Wook Lee

Department of Anesthesiology and Pain Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea

Background: Postoperative nausea and vomiting (PONV) is one of the major concerns after anesthesia and surgery, and it may be more frequent in orthopedic patients receiving patient-controlled epidural analgesia (PCEA). The purpose of this study was to compare the effect of palonosetron and dexamethasone on the prevention of PONV in patients undergoing total joint arthroplasty and receiving PCEA.

Methods: Patients scheduled for total hip or knee arthroplasty under spinal anesthesia/PCEA were randomly allocated to receive either intravenous palonosetron (0.075 mg, n = 50) or dexamethasone (5 mg, n = 50). Treatments were administered intravenously to the patients 30 min before the beginning of surgery. The total incidence of PONV and incidence in each time period, severity of nausea, need for rescue anti-emetics, pain score, and adverse effects during the first 48 h postoperatively were evaluated.

Results: The total incidence of PONV was lower in the palonosetron group compared with the dexamethasone group (18.4% vs. 36.7%, P = 0.042), but there were no statistically significant differences in incidence between the groups at all time points. No significant intergroup differences were observed in the severity of nausea, use of rescue anti-emetics, pain score, and adverse effects.

Conclusions: Although there were no significant differences in the incidence of PONV between the treatment groups at all time points, intravenous palonosetron reduced the total incidence of PONV in orthopedic patients receiving PCEA compared with dexamethasone.

Key Words: Dexamethasone, Epidural analgesia, Palonosetron, Patient-controlled analgesia, Postoperative nausea and vomiting.
Introduction

Postoperative pain control is essential for fast functional recovery through early rehabilitation, early return to daily life, and the welfare of patients after orthopedic limb surgery. Compared with intravenous patient-controlled analgesia (PCA), patient-controlled epidural analgesia (PCEA) enables effective pain control, fast intestinal motility recovery, and shortened hospital stay [1]. However, PCEA may result in several side effects due to the combined use of both local anesthetic and opioids [2-4]. Among the side effects, postoperative nausea and vomiting (PONV) occurs frequently and has a major negative impact on patient satisfaction. PONV can be caused by either the surgery or the anesthesia itself, but it can also be caused by the opioid contained in the PCEA [2,3,5].

Dexamethasone is known to reduce the incidences of PONV in children and adults [6]. Tarantino et al. [7] reported that the use of dexamethasone is effective in reducing nausea and vomiting by 28% after thyroidectomy. It was also effective in preventing nausea and vomiting associated with epidural opioid in patients undergoing open gynecologic surgery [4]. However, the use of dexamethasone may result in a reduction in glycemic control capability, increased wound infection or delayed wound healing, gastritis, and avascular necrosis [8].

Serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have been commonly used to prevent chemotherapy-induced nausea and vomiting, as well as PONV [9,10]. Compared with older 5-HT3 receptor antagonists, palonosetron has been widely used in recent years because of its advantages such as no QTc prolongation and longer half-life. However, there is little information about the use of palonosetron as prophylaxis against nausea and vomiting induced by PCEA containing opioids.

Therefore, the purpose of this study was to compare the effects of palonosetron and dexamethasone on PONV in patients undergoing total joint arthroplasty and receiving PCEA. The primary outcome was the overall incidence of PONV during the first 48 h postoperatively. Secondary outcomes were the incidence of PONV at 2, 24, and 48 h, the severity of nausea, use of rescue anti-emetics, pain scores, and side effects.

Materials and Methods

Institutional Review Board approval and written informed consent were obtained for this randomized, double-blind study. A total of 100 patients aged 20 to 80 years with an American Society of Anesthesiologists physical status of 1 to 3 who were scheduled to undergo total hip or knee arthroplasty and who wished to receive PCEA for postoperative pain control were recruited. Exclusion criteria were contraindication to regional anesthesia (coagulation disorders and infection at the injection site), pregnancy, administration of anti-emetics or steroids within 24 h before surgery, liver or kidney disease, neuropsychiatric disorders, and hypersensitivity to local anesthetic.

Using a computer-generated sequence of random numbers and sealed envelopes, patients were assigned to either the palonosetron group (group P) or dexamethasone group (group D). All envelopes were opened after induction of anesthesia by an attending nurse who was not involved in the study. The patients, anesthesiologists who performed the blocks, surgeons, and research assistants collecting outcome data were blinded to group allocation.

After arriving at the operating room, the patients were monitored continuously for blood pressure, heart rate, electrocardiogram, and peripheral oxygen saturation. Before induction, the patients received glycopyrrolate 0.2 mg and midazolam 2 mg intravenously.

In both groups, patients received combined spinal–epidural anesthesia with subarachnoid administration of 8 mg of 0.5% hyperbaric bupivacaine at the L3–4 or L4–5 intervertebral space with the patient in the lateral decubitus position. Then, using an 18 G Tuohy needle, the epidural space was confirmed by the method of loss of resistance using 1.5–2 ml air at the same level. A catheter was passed cephalad 3 cm past the needle tip and fixed after checking that no blood or cerebrospinal fluid was aspirated. Sensory blockade was targeted for over T12 and it was tested by a pin-prick test every 5 minutes for up to 15 minutes after the injection. If the sensory block was insufficient, 5 ml of 0.75% ropivacaine was injected through the epidural catheter as supplementation.

Patients were treated with prophylactic antibiotics 30 min before the beginning of the surgery. The study drugs (palonosetron 0.075 mg for group P and dexamethasone 5 mg for group D, respectively) were administered to the patients in each group prior to the injection of prophylactic antibiotics. The study drug for injection was prepared as 1 ml of clear solution in identical syringes.

Supplemental oxygen was administered throughout the procedure at 6 L/min through a mask. All the patients received an intravenous infusion of dexmedetomidine (loading dose of 0.1 μg/kg/min over 10 min followed by 0.008 μg/kg/min) for sedation throughout the procedure. Doses were adjusted to maintain a bispectral index value between 60 and 70. If the value fell more than 20% compared with the baseline blood pressure, ephedrine 10 mg was given. Every 60 min after the start of surgery, 5 ml of 0.75% ropivacaine was injected through the epidural catheter. On arrival at the postanesthesia care unit, an infusion of 0.2% ropivacaine (100 ml in total) and 1 μg/ml sufentanil (100 ml in total) was started and continued for 48 h (2 ml/h basal; 0.5 ml bolus; 15 min lockout) using an elastomeric infusion pump.
The incidence of PONV (nausea, retching, and vomiting) and severity of nausea were recorded by direct questioning by research assistants blinded to the study group or recorded by the patients at the time points of 2, 24, and 48 h in reference to symptom occurrence during the prior observation period. Nausea was defined as the subjectively unpleasant sensation associated with awareness of the urge to vomit regardless of its severity. For the purpose of data collection, vomiting included retching (an involuntary attempt to vomit but without expulsion of gastric content) and vomiting (expulsion of gastric content). If nausea or vomiting was documented at any of these time points, it was considered PONV. The severity of nausea was rated from 0 (no nausea) to 10 (worst possible nausea). Rescue anti-emetics (ondansetron 4 mg) were given for PONV upon patient’s request or complaint of nausea (severity of nausea ≥ 4) or vomiting and the number of injections was noted. Postoperative pain was assessed using a numerical rating scale (NRS, 0 = no pain; 10 = worst imaginable pain) at 2, 24, and 48 h after surgery. Rescue analgesia with 25 mg of intravenous meperidine to a maximum of 75 mg/24 h was available on demand. Other adverse effects, such as headache, dizziness, drowsiness, pruritus, constipation, wound infection or delayed wound healing, paresthesia, and motor weakness were also recorded.

Statistical analysis

SPSS version 19 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Normality of the data was tested using the Kolmogorov–Smirnov test. Normally distributed continuous variables were presented as means and SD and analyzed using Student’s t-test. Non-normally distributed data were presented as median with 25th and 75th percentiles and analyzed using the Mann–Whitney U test. Categorical variables were defined as the number of patients (%) and analyzed using the Chi-square test or Fisher’s exact test, as appropriate. A P value < 0.05 was considered statistically significant. Bonferroni correction for multiple repeated measurements was used for analysis of incidence of PONV at any time point, severity of nausea, and pain scores. In this case, a P value < 0.017 (= 0.05/3) was considered significant.

Sample size calculation was based on a previous study, which observed a 40% incidence of PONV in the dexamethasone group after surgery [11]. Assuming a 10% incidence of PONV in the palonosetron group, it was estimated that the sample size should be 40 patients per group using α = 0.05 and β = 0.1 for a two-sided test of difference. We enrolled 50 patients per group to allow for possible dropouts.
Results

One hundred patients were enrolled in this study. One patient from each group was excluded because of a technical failure of spinal or epidural block. A total of 98 patients were included in the study (Fig. 1). Patient characteristics, Apfel risk score, type of surgery, and duration of the operation were comparable in both groups (Table 1).

The total incidence of PONV was significantly lower in the group P than group D (18.4% vs. 36.7%, P = 0.042, Table 2). However, there were no statistically significant differences in both groups during the 0–2 h, 2–24 h, and 24–48 h periods (Table 2). The severity of postoperative nausea was not significantly different between the two groups at all time intervals after surgery (Table 3). The numbers of patients requiring rescue anti-emetics were not significantly different between the groups (P = 0.372, Table 3).

There was no statistically significant difference in postoperative pain during the study periods (Table 3). In addition, supplemental meperidine consumption was similar between both groups (P = 0.176, Table 3). One patient in each group complained dizziness. There were no significant differences between the two groups considering potential adverse effects.

Discussion

This study demonstrated that palonosetron resulted in a lower total incidence of PONV than dexamethasone in patients receiving PCEA after hip or knee replacement surgery. However, there were no differences in the incidence of PONV at any time point, severity of nausea, use of rescue anti-emetics, pain score, and adverse effects.

PONV is one of a major contributing factor that negatively influences patient satisfaction after surgery. Although a contributor to PONV has not been clearly proven till now, various

| Table 1. Demographic and Clinical Data |
|----------------------------------------|
| **Group P (n = 49)** | **Group D (n = 49)** |
| Age (yr) | 63 ± 11 | 62 ± 11 |
| Sex (F) | 36 | 31 |
| Weight (kg) | 61 ± 11 | 66 ± 11 |
| Height (cm) | 156 ± 10 | 160 ± 9 |
| Apfel risk score | | |
| 1 | 5 | 5 |
| 2 | 9 | 14 |
| 3 | 31 | 24 |
| 4 | 4 | 6 |
| Type of surgery | | |
| THA | 16 | 22 |
| TKA | 33 | 27 |
| Operation time (min) | 128 ± 52 | 131 ± 53 |

Values are expressed as mean ± SD or number of patients. Group P: palonosetron 0.075 mg IV, Group D: dexamethasone 5 mg IV. THA: total hip arthroplasty, TKA: total knee arthroplasty.

| Table 2. Incidence of PONV |
|---------------------------|
| **Group P (n = 49)** | **Group D (n = 49)** | **P value** |
| Total incidence | 9 (18.4) | 18 (36.7) | 0.042 |
| 0–2 h* | 0 (0) | 2 (4.1) | 0.093 |
| 2–24 h* | 8 (16.3) | 16 (32.7) | 0.060 |
| 24–48 h* | 5 (10.4) | 14 (28.6) | 0.024 |

Values are number of patients (%). Group P: palonosetron 0.075 mg IV, Group D: dexamethasone 5 mg IV. PONV: postoperative nausea and vomiting. *A significant P value as determined by Bonferroni-adjusted alpha level (α = 0.017) in individual comparisons between 0–2 h, 2–24 h, and 24–48 h periods.

| Table 3. Severity of Nausea, Use of Rescue Anti-emetic, Pain Score, and Use of Rescue Opioid |
|-----------------------------------------------|
| **Group P (n = 49)** | **Group D (n = 49)** | **P value** |
| Severity of nausea (NRS 0–10) |
| 0–2 h* | 0 (0–0) | 0 (0–0) | 0.153 |
| 2–24 h* | 0 (0–0) | 0 (0–2.5) | 0.060 |
| 24–48 h* | 0 (0–0) | 0 (0–1.5) | 0.024 |
| Rescue anti-emetics | 5 (10.2) | 8 (16.3) | 0.372 |
| Pain (NRS 0–10) |
| At 2 h† | 0 (0–0) | 0 (0–0) | 0.118 |
| At 24 h† | 3.5 (3–5) | 3 (3–5) | 0.686 |
| At 48 h† | 3 (3–5) | 3 (2–3) | 0.074 |
| Rescue opioid consumption (mg) | 0 (0–25) | 0 (0–25) | 0.176 |
| No. of patients requiring rescue opioid | 24 (49.0) | 17 (35.4) | 0.176 |

Values are median (25th, 75th percentiles) or number of patients (%). Group P: palonosetron 0.075 mg IV, Group D: dexamethasone 5 mg IV. NRS: numerical rating scale. *A significant P value as determined by Bonferroni-adjusted alpha level (α = 0.017) in individual comparisons between 0–2 h, 2–24 h, and 24–48 h periods. †A significant P value as determined by Bonferroni-adjusted alpha level (α = 0.017) in individual comparisons between 2 h, 24 h, and 48 h time points.
Palonosetron is the newest 5-HT\textsubscript{3} receptor antagonist, with a greater receptor binding affinity than the older 5-HT\textsubscript{3} receptor antagonists and a longer half-life of 40 hours. A recent study [17] showed that a single dose of palonosetron 0.075 mg reduced the incidence of PONV during the first 72 h after surgery. It was more effective in the prevention of PONV than older 5-HT\textsubscript{3} receptor antagonists [18]. Furthermore, combination treatment using palonosetron and dexamethasone was more effective in the prevention of PONV compared with dexamethasone only in patients receiving IV PCA after general anesthesia [10]. A recent study reported that palonosetron was more effective in the prevention of PONV than ramosetron after cesarean section under spinal anesthesia [19]. A previous study evaluated older 5-HT\textsubscript{3} receptor antagonists for the prophylaxis of PONV in patients receiving PCEA containing an opioid after total knee arthroplasty [20]. Compared with ondansetron, ramosetron was more effective in preventing PONV associated with PCEA. However, few studies have compared palonosetron with dexamethasone in preventing nausea and vomiting associated with continuous administration of epidural opioid.

In this study, there were no differences in pain scores and consumption of supplemental analgesics between the two groups. A previous study reported that the 5-HT\textsubscript{3} receptor is involved in the modulation of nociceptive transmission [21]. Lee et al. [22] reported that the pain score in the palonosetron group was lower than that of the control group. In addition, in a previous study on the effects of dexamethasone on pain, administration of dexamethasone resulted in reduced pain score, length of hospital stay, and opioid consumption compared with control patients undergoing cesarean section after the administration of epidural morphine [16].

Consistent with previous studies, there were no adverse effects observed in this study, such as dizziness, drowsiness, constipation, headache, and wound infection [10,14,16]. The long-term use of corticosteroids was associated with several side effects, such as increased risk of infection, glucose intolerance, delayed wound healing, superficial ulceration of gastric mucosa, and adrenal suppression, but no hazards were shown with a single dose [16]. Allen et al. [14] reported that there were no side effects, such as delayed wound healing, wound infection, and restlessness, when 2.5–10 mg dexamethasone was administered to parturients receiving epidural morphine. Headache and dizziness are the most common side effects of the 5-HT\textsubscript{3} receptor antagonist. However, a previous study reported that there was not significantly different in the incidence of side effects between the palonosetron and placebo groups [17].

This study has some limitations. First, although we compared two different anti-emetics, combination anti-emetic therapy is recommended for patients at moderate or high risk of PONV [12]. Second, we used ondansetron as rescue anti-emetics in this study. Since it is also a 5-HT\textsubscript{3} receptor antagonist, an anti-emetic with a different mechanism is more desirable. Third, midazolam and dexmedetomidine were administered to achieve intravenous sedation of patients during sensory block and surgery, respectively. These drugs have an anti-emetic effect [24,25].
Fourth, we did not include a placebo control group to evaluate the baseline incidence of PONV. However, it is unethical to withhold anti-emetics in patients at high risk of PONV. Finally, patient satisfaction was not included as an outcome variable in this study. It is an important patient-reported endpoint.

In conclusion, this study demonstrated that intravenous palonosetron reduced the total incidence of PONV in orthopedic patients receiving PCEA compared with dexamethasone.

Acknowledgments

This study was supported by an Inha University Research grant.

The authors would like to thank all the study participants for their participation in this study.

ORCID

Hyun Kyoung Lim, https://orcid.org/0000-0003-2694-1258
Chunwoo Yang, https://orcid.org/0000-0002-9147-3879

References

1. Zhu Z, Wang C, Xu C, Cai Q. Influence of patient-controlled epidural analgesia versus patient-controlled intravenous analgesia on postoperative pain control and recovery after gastrectomy for gastric cancer: a prospective randomized trial. Gastric Cancer 2013; 16: 193-200.
2. Chaney MA. Side effects of intrathecal and epidural opioids. Can J Anaesth 1995; 42: 891-903.
3. Gadsden J, Hart S, Santos AC. Post-cesarean delivery analgesia. Anesth Analg 2005; 101(5 Suppl): S62-9.
4. Ho ST, Wang JJ, Tseng JJ, Liu HS, Ger LP, Liaw WJ. Dexamethasone for preventing nausea and vomiting associated with epidural morphine: a dose-ranging study. Anesth Analg 2001; 92: 745-8.
5. Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anaesth 2004; 51: 326-41.
6. Henzi I, Walker B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000; 90: 186-94.
7. Tarantino I, Warschkow R, Beutner U, Kolb W, Lüthi A, Lüthi C, et al. Efficacy of a single preoperative dexamethasone dose to prevent nausea and vomiting after thyroidectomy (the tPONV study): a randomized, double-blind, placebo-controlled clinical trial. Ann Surg 2015; 262: 934-40.
8. Ho CM, Wu HL, Ho ST, Wang JJ. Dexamethasone prevents postoperative nausea and vomiting: benefit versus risk. Acta Anaesthesiol Taiwan 2011; 49: 100-4.
9. Gralla R, Lichinitser M, Van Der Vegt S, Sleebom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7.
10. Ryoo SH, Yoo JH, Kim MG, Lee KH, Kim SI. The effect of combination treatment using palonosetron and dexamethasone for the prevention of postoperative nausea and vomiting versus dexamethasone alone in women receiving intravenous patient-controlled analgesia. Korean J Anesthesiol 2015; 68: 267-73.
11. Lee HK, Lee JH, Chon SS, Ahn EK, Kim JH, Jang YH. The effect of transdermal scopolamine plus intravenous dexamethasone for the prevention of postoperative nausea and vomiting in patients with epidural PCA after major orthopedic surgery. Korean J Anesthesiol 2010; 58: 50-5.
12. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118: 85-113.
13. Smith HS, Laufer A. Opioid induced nausea and vomiting, Eur J Pharmacol 2014; 722: 67-78.
14. Allen TK, Jones CA, Habib AS. Dexamethasone for the prophylaxis of postoperative nausea and vomiting associated with neuraxial morphine administration: a systematic review and meta-analysis. Anesth Analg 2012; 114: 813-22.
15. Lee Y, Lai HY, Lin PC, Lin YS, Huang SJ, Shyr MH. A dose ranging study of dexamethasone for preventing patient-controlled analgesia-related nausea and vomiting: a comparison of droperidol with saline. Anesth Analg 2004; 98: 1066-71.
16. Wang JJ, Ho ST, Wong CS, Tseng JJ, Liu HS, Ger LP. Dexamethasone prophylaxis of nausea and vomiting after epidural morphine for post-Cesarean analgesia. Can J Anaesth 2001; 48: 185-90.
17. Chun HR, Jeon IS, Park SY, Lee SJ, Kang SH, Kim SI. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial. Br J Anaesth 2014; 112: 485-90.
18. Singh PM, Borle A, Gouda D, Makkar JK, Arora MK, Trikha A, et al. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis. J Clin Anesth 2016; 34: 459-82.
19. Chattopadhyay S, Goswami S. Palonosetron versus ramosetron prophylaxis for control of postoperative nausea and vomiting after cesarean surgery. J Clin Anesth 2016; 34: 459-82.
Palonosetron vs. dexamethasone for PONV

delivery under spinal anesthesia. J Obstet Gynaecol India 2015; 65: 28-33.
20. Hahm TS, Ko JS, Choi SJ, Gwak MS. Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement. Anaesthesia 2010; 65: 500-4.
21. Faerber L, Drechsler S, Ladenburger S, Gschaidmeier H, Fischer W. The neuronal 5-HT \textsubscript{3} receptor network after 20 years of research--evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007; 560: 1-8.
22. Lee KH, Rim SK, Lee JY, Lee SY, Lee SN, Lee EJ, et al. Effects of pretreatment with intravenous palonosetron for propofol-remifentanil-based anesthesia in breast and thyroid cancer surgery: a double-blind, randomized, controlled study. Korean J Anesthesiol 2014; 67: 13-9.
23. Backes JR, Bentley JC, Politi JR, Chambers BT. Dexamethasone reduces length of hospitalization and improves postoperative pain and nausea after total joint arthroplasty: a prospective, randomized controlled trial. J Arthroplasty 2013; 28(8 Suppl): 11-7.
24. Splinter WM, MacNeill HB, Menard EA, Rhine EJ, Roberts DJ, Gould MH. Midazolam reduces vomiting after tonsillectomy in children. Can J Anaesth 1995; 42: 201-3.
25. Liang X, Zhou M, Feng JI, Wu L, Fung SP, Ge XY, et al. Efficacy of dexmedetomidine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015; 8: 8450-71.